Spoken Alpha
JNJ
JOHNSON & JOHNSON
Overview
Johnson & Johnson manufactures and sells pharmaceutical medicines and medical devices for treating cancer, immunological disorders, neurological conditions, infectious diseases, cardiovascular disease, and other health conditions, as well as surgical instruments, orthopedic products, and vision care products to hospitals, physicians, healthcare professionals, and consumers worldwide.
JOHNSON & JOHNSON is a Healthcare company operating in Drug Manufacturers - General with a $573.98B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 14, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-149 Q&A exchanges
- Q4 FY2025Earnings2026-01-219 Q&A exchanges
- Q3 FY2025Earnings2025-10-1412 Q&A exchanges
- Q2 FY2025Earnings2025-07-169 Q&A exchanges
- Q1 FY2025Earnings2025-04-159 Q&A exchanges
- Q4 FY2024Earnings2025-01-228 Q&A exchanges
- Q3 FY2024Earnings2024-10-158 Q&A exchanges
- Q2 FY2024Earnings2024-07-1710 Q&A exchanges
- Q1 FY2024Earnings2024-04-1610 Q&A exchanges
- Q4 FY2023Earnings2024-01-2312 Q&A exchanges
- Q3 FY2023Earnings2023-10-1712 Q&A exchanges
- Q2 FY2023Earnings2023-07-208 Q&A exchanges
- Q1 FY2023Earnings2023-04-189 Q&A exchanges
- Q4 FY2022Earnings2023-01-248 Q&A exchanges
- Q3 FY2022Earnings2022-10-189 Q&A exchanges
- Q2 FY2022Earnings2022-07-198 Q&A exchanges
- Q1 FY2022Earnings2022-04-1910 Q&A exchanges
- Q4 FY2021Earnings2022-01-259 Q&A exchanges
- Q3 FY2021Earnings2021-10-198 Q&A exchanges
- Q2 FY2021Earnings2021-07-2111 Q&A exchanges
- Q1 FY2021Earnings2021-04-2014 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-14EPS— vs $2.85—Rev— vs ——EODHD
- Q1 FY20262026-04-13EPS$2.70 vs $2.68+0.8%Rev$24.06B vs ——EODHD
- Q4 FY20252026-01-20EPS$2.46 vs $2.460.0%Rev$24.56B vs ——EODHD
- Q3 FY20252025-10-13EPS$2.80 vs $2.76+1.5%Rev$23.99B vs ——EODHD
- Q2 FY20252025-07-15EPS$2.77 vs $2.68+3.4%Rev$23.74B vs ——EODHD
- Q1 FY20252025-04-14EPS$2.77 vs $2.58+7.4%Rev$21.89B vs ——EODHD
- Q4 FY20242025-01-21EPS$2.04 vs $2.01+1.5%Rev$22.52B vs ——EODHD
- Q3 FY20242024-10-14EPS$2.42 vs $2.21+9.5%Rev$22.47B vs ——EODHD
- Q2 FY20242024-07-16EPS$2.82 vs $2.70+4.4%Rev$22.45B vs ——EODHD
- Q1 FY20242024-04-15EPS$2.20 vs $2.21-0.4%Rev$21.38B vs ——EODHD
- Q4 FY20232024-01-22EPS$2.29 vs $2.28+0.4%Rev$21.39B vs ——EODHD
- Q3 FY20232023-10-16EPS$2.66 vs $2.52+5.6%Rev$21.35B vs ——EODHD
- Q2 FY20232023-07-19EPS$2.80 vs $2.62+6.9%Rev$21.52B vs ——EODHD
- Q1 FY20232023-04-17EPS$2.68 vs $2.50+7.2%Rev$20.89B vs ——EODHD
- Q4 FY20222023-01-23EPS$2.35 vs $2.24+4.9%Rev$23.71B vs ——EODHD
- Q3 FY20222022-10-17EPS$2.55 vs $2.49+2.4%Rev$23.79B vs ——EODHD
- Q2 FY20222022-07-18EPS$2.59 vs $2.55+1.6%Rev$24.02B vs ——EODHD
- Q1 FY20222022-04-18EPS$2.67 vs $2.57+3.9%Rev$23.43B vs ——EODHD
- Q4 FY20212022-01-24EPS$2.13 vs $2.12+0.5%Rev$24.80B vs ——EODHD
- Q3 FY20212021-10-18EPS$2.60 vs $2.35+10.6%Rev$23.34B vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-14 | — | $2.85 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-04-13 | $2.70 | $2.68 | +0.8% | $24.06B | — | — | EODHD |
| Q4 FY2025 | 2026-01-20 | $2.46 | $2.46 | 0.0% | $24.56B | — | — | EODHD |
| Q3 FY2025 | 2025-10-13 | $2.80 | $2.76 | +1.5% | $23.99B | — | — | EODHD |
| Q2 FY2025 | 2025-07-15 | $2.77 | $2.68 | +3.4% | $23.74B | — | — | EODHD |
| Q1 FY2025 | 2025-04-14 | $2.77 | $2.58 | +7.4% | $21.89B | — | — | EODHD |
| Q4 FY2024 | 2025-01-21 | $2.04 | $2.01 | +1.5% | $22.52B | — | — | EODHD |
| Q3 FY2024 | 2024-10-14 | $2.42 | $2.21 | +9.5% | $22.47B | — | — | EODHD |
| Q2 FY2024 | 2024-07-16 | $2.82 | $2.70 | +4.4% | $22.45B | — | — | EODHD |
| Q1 FY2024 | 2024-04-15 | $2.20 | $2.21 | -0.4% | $21.38B | — | — | EODHD |
| Q4 FY2023 | 2024-01-22 | $2.29 | $2.28 | +0.4% | $21.39B | — | — | EODHD |
| Q3 FY2023 | 2023-10-16 | $2.66 | $2.52 | +5.6% | $21.35B | — | — | EODHD |
| Q2 FY2023 | 2023-07-19 | $2.80 | $2.62 | +6.9% | $21.52B | — | — | EODHD |
| Q1 FY2023 | 2023-04-17 | $2.68 | $2.50 | +7.2% | $20.89B | — | — | EODHD |
| Q4 FY2022 | 2023-01-23 | $2.35 | $2.24 | +4.9% | $23.71B | — | — | EODHD |
| Q3 FY2022 | 2022-10-17 | $2.55 | $2.49 | +2.4% | $23.79B | — | — | EODHD |
| Q2 FY2022 | 2022-07-18 | $2.59 | $2.55 | +1.6% | $24.02B | — | — | EODHD |
| Q1 FY2022 | 2022-04-18 | $2.67 | $2.57 | +3.9% | $23.43B | — | — | EODHD |
| Q4 FY2021 | 2022-01-24 | $2.13 | $2.12 | +0.5% | $24.80B | — | — | EODHD |
| Q3 FY2021 | 2021-10-18 | $2.60 | $2.35 | +10.6% | $23.34B | — | — | EODHD |
Source: EODHD. JNJ reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks JNJ's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.56 | $1.98 | -21.4% | +7.3% | +5.9% |
| Q4 FY2026 | $1.68 | $2.09 | -19.8% | +3.1% | +2.5% |
| Q3 FY2026 | $1.40 | $1.96 | -28.8% | +6.1% | +4.0% |
| Q2 FY2026 | $1.68 | $2.05 | -18.0% | -2.6% | -0.7% |
| Q1 FY2025 | $1.57 | $2.12 | -25.9% | -2.8% | -4.5% |
| Q4 FY2025 | $1.78 | $2.25 | -21.0% | +7.9% | +6.2% |
| Q3 FY2025 | $1.77 | $2.06 | -14.2% | +6.9% | +4.5% |
| Q2 FY2025 | $1.62 | $2.27 | -28.7% | +7.6% | +6.6% |
| Q1 FY2024 | $1.78 | $2.19 | -18.7% | -2.6% | -3.7% |
| Q4 FY2024 | $1.76 | $2.13 | -17.3% | +6.1% | +5.0% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Joaquin DuatoCEO4 mo16 callsCurrentSample
CEO since 2026 • 2/2 beats (100%) • guidance suspended Q3 FY2026
- Joseph J WolkCFO4 mo21 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
- James D SwansonEVP, CIO4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last call held guidance Q3 FY2026
- Elizabeth ForminardEVP, Chief Legal Officer4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last call held guidance Q1 FY2026
- Kristen MulhollandEVP, Chief HR Officer4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- John C ReedEVP, Innovative Medicine, R&D4 mo10 callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for JNJ.
$ curl https://api.spokenalpha.com/v1/companies/JNJFAQ
Frequently asked about JNJ
Where can I find JOHNSON & JOHNSON's (JNJ) earnings call transcripts?
Spoken Alpha indexes JNJ's earnings call transcripts at https://spokenalpha.com/companies/JNJ. Each call links to attributed speakers and parsed analyst Q&A. JOHNSON & JOHNSON's own investor relations page is at https://www.investor.jnj.com/overview/default.aspx.
When was JOHNSON & JOHNSON's most recent earnings call?
JOHNSON & JOHNSON (JNJ) held its most recent earnings call on 2026-04-14, covering fiscal Q1 2026.
What sector is JNJ in?
JOHNSON & JOHNSON (JNJ) operates in the Healthcare sector (Drug Manufacturers - General industry).